Grantham's favorite stat on Tesla's overvaluation is that the market values the company at $1.25 million per car sold. That is a wee bit more than the $9,000 per car sold that General Motors' (NYSE: GM) valuation reflects. Grantham's other red flags include... The "Buffett indicator," a ratio of total stock market capitalization to GDP, is now breaking through its all-time high, which was hit during the 2000 dot-com bubble. An astounding 480 initial public offerings (IPOs) took place in 2020 as companies rushed to take advantage of screaming investor demand (once again exceeding the 2000 bubble record of 406). A total of 150 non-microcap companies (that is, those with market capitalizations of more than $250 million) have more than tripled in 2020, which is more than three times as many as any year in the previous decade. The volume of small retail purchases of call options on U.S. equities has increased eightfold compared with 2019's volume, which means the small investor is now straight-up gambling.
What Is an Investor to Do? Now the good news... Grantham goes on to write that, as often happens in the midst of major market bubbles, there are extreme valuation disparities by asset class, sector and company. In other words, while the popular stocks are horrifyingly expensive, the areas of the market that are out of favor are very cheap. For the most expensive stocks in the market, the risk of loss for investors has rarely been higher. But in the out-of-favor sectors, there are terrific bargains to be found. And Grantham sees value in the same places I have been writing about for months. For instance, he believes that value stocks have never been more attractively valued relative to growth stocks. This is a deeply out-of-favor part of the market. Value stocks are coming off their worst decade in history relative to growth stocks, and they started the current decade by performing even worse. That incredibly long run of underperformance has created a major opportunity. The cycle is due to turn back in favor of value and away from growth. You can read more about this return to value here. Grantham's second call is for emerging market stocks. He notes that emerging markets are at 50-year valuation lows relative to U.S. stocks. Again, this opportunity has been set up by a long period of underperformance. I detailed how emerging market stocks are trading at half the valuation of U.S. stocks back in October. Grantham's historical track record of spotting bubbles in real time is very good. I believe it is wise to listen to him, but I would note that he is almost always early. That gives us time to pivot our portfolios away from the dangerously expensive areas of the market and into more attractively priced opportunities. The time to start doing that is now. Good investing, Jody P.S. Biotech is another area where, even if a rest comes, there are still bargains to be found. And Chief Income Strategist Marc Lichtenfeld is an expert at isolating those opportunities and handing his readers the chance at giant wins - like up to 2,381% in 10 months on AbbVie's (NYSE: ABBV) call options. Click here to learn how you can join him and collect up to 3,000% in a single year. But hurry - this is the only way you can still get in on his offer. | 
No comments:
Post a Comment